Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VUM02 + BAT
- Development stage
- Unknown
- Lead developer
- 武汉光谷中源药业
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
VUM02 + BAT is a combination therapy consisting of VUM02 (human umbilical cord-derived mesenchymal stromal/stem cells, hUC-MSC) and BAT. VUM02 is an allogeneic cell therapy product comprising culture-expanded mesenchymal stem cells derived from human umbilical cord tissue. It is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF) and steroid-refractory acute graft-versus-host disease (SR-aGvHD). The mechanism of action for VUM02 involves stem cell therapy, specifically leveraging the immunomodulatory and regenerative properties of mesenchymal stem cells. The identity or role of "BAT" in this combination could not be determined from available sources; no clinical or preclinical data were found describing a drug or agent named "BAT" in combination with VUM02. VUM02 is developed by Wuhan Optics Valley Vcanbiopharma Co., Ltd., with clinical trials ongoing in China for IPF and SR-aGvHD.
Beyond the preview
Go deeper on VUM02 + BAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VUM02 + BAT.